Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
Roche's obesity ambition not reliant on one megablockbuster
Roche’s head of metabolic development said the company is firing “on full cylinders” to get a phase 3 trial of its GLP-1/GIP drug launched next year.
James Waldron
Sep 23, 2025 7:45am
Roche unveils strategy to become 'top 3' obesity company
Sep 22, 2025 8:05am
What’s next for Roche’s expensive obesity pipeline?
Sep 19, 2025 10:16am
Lilly rounds out orforglipron data ahead of obesity filings
Sep 17, 2025 9:00am
Novo pushes ahead with amylin after seeing ph. 3 tolerability
Sep 16, 2025 8:12am
Fierce Pharma
Novo charts major restructuring, layoffs under new CEO
Sep 10, 2025 8:41am
